Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01526096 · ClinicalTrials.gov registry record · Phase 1
Stem Cell Transplantation for Patients With Multiple Myeloma
A Phase 1 study of Myeloma, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01526096: Completed Phase 1 study of Myeloma, sponsored by University of Chicago.
NCT01526096 is a Phase 1 study of Myeloma that has completed, run by University of Chicago. The registered enrollment target is 30 participants, below the 99-participant average among 29 other Myeloma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01526096, a Phase 1 study of Myeloma, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test whether regulatory T-cell reduction is possible and safe in myeloma subjects undergoing autologous stem cell transplantation (ASCT).
Primary Outcome
Percentage of CD4+CD25+ regulatory T cells following ex vivo depletion in arm 3 will be analyzed by flow cytometry and compared to a pre-CD25-depletion sample. The depletion of CD25+ cells among the entire CD4+ population is expected to reach 80% efficiency.
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG G-CSF
- PROCEDURE Apheresis
- DRUG Plerixafor
- PROCEDURE Stem cell re-infusion
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-07-12 |
| Est. Completion | 2024-08-28 |
| Phase | Phase 1 |
What the finished NCT01526096 record still lists
NCT01526096 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 99-participant average among 29 other Myeloma trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.
NCT01526096 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT01526096 about?
NCT01526096 is a clinical study titled "Stem Cell Transplantation for Patients With Multiple Myeloma". The purpose of this study is to test whether regulatory T-cell reduction is possible and safe in myeloma subjects undergoing autologous stem cell transplantation (ASCT).
What is the current status of trial NCT01526096?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2011-07-12. Estimated completion is 2024-08-28.
What conditions does trial NCT01526096 study?
This clinical trial studies the following conditions: Myeloma.
What interventions are being tested in trial NCT01526096?
The interventions under investigation include: Melphalan (DRUG), G-CSF (DRUG), Apheresis (PROCEDURE), Plerixafor (DRUG), Stem cell re-infusion (PROCEDURE).
Who is sponsoring clinical trial NCT01526096?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01526096 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01526096's enrollment target sits among peer trials
30 23rd of 29 higher than 5 of 29 other Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 1
-
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
RECRUITING · Phase 1
-
Pilot Imaging Study of Leukemia
RECRUITING · Phase 1
-
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI